Takeda-backed Ascentage Pharma Group (AAPG) (ASPHF), which is developing treatments for blood cancers, has set terms for a ...

Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

China's Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering in the U.S., in what could be the first listing of a healthcare company in 2025.

aTyr Pharma, Inc. (Nasdaq ... today announced that the Company will be changing its ticker symbol from “LIFE” to “ATYR.” Effective at the market open on June 5, 2024, the Company ...

List today: CareDx, Inc CDNA: This diagnostic solutions company for transplant patients and caregivers has seen the Zacks ...

Through its engagement with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border provides a convenient one-stop solution for Mainland ...

Generics businesses achieve pretty defendable margins, yet their valuations are at material discounts to most of the Big ...

The company expects to generate gross proceeds of $4 million, with $2.9 million in net proceeds after expenses.

Ms. Andor will lead the Company's expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating oral levosimendan (TNX-103) for the treatment of pulmonary hypertension ...